Glycaemic Alterations in ICU
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02516358|
Recruitment Status : Unknown
Verified August 2015 by Francesca Di Muzio, Catholic University of the Sacred Heart.
Recruitment status was: Not yet recruiting
First Posted : August 5, 2015
Last Update Posted : September 1, 2015
|Condition or disease|
The aim of this study is to determine the local prevalence of critical illness-associated hyperglycaemia (CIAH) and recognised and unrecognised diabetes, as well as to evaluate how premorbid glycaemia impacts the relationship between three glycaemic domains and mortality.
The investigators will calculate the Time In Range (TIR, 70-180 mg/dl) and evaluate distribution of percentage time in range for non-diabetics and diabetics patients, in order to understand the association between TIR and survival in both groups of patients (patients with diabetes and patients without diabetes).
In view of the potential adverse effects of hyperglycaemia, hypoglycaemia and glycaemic variability on the brain, the investigators will dose Neuron Specific Enolase in critically ill patients.
The aim is to define if a biochemical correlation does exist between critically ill dysglycaemia and NSE plasma concentration.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Glycaemic Alterations in ICU: an Observational, Prospective Cohort Study|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||February 2016|
|Estimated Study Completion Date :||September 2016|
- Change in glycaemic blood levels during ICU stay [ Time Frame: Glycaemic values expressed as mean glycaemia will be collected at the baseline and every 8 hours for the duration of ICU stay, expected average of 10 days per patient. ]
- Episodes of hypoglicaemia (number) [ Time Frame: For the duration of ICU stay, expected average of 10 days per patient. ]
- Episodes of hyperglycaemia (number) [ Time Frame: For the duration of ICU stay, expected average of 10 days per patient. ]
- Coefficient of variation of blood glucose levels [ Time Frame: Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient. ]Coefficient of Variation, calculated as a percentage
- Time in glycaemic Range (TIR) [ Time Frame: Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient. ]Evaluated in hours TIR/ total hours in ICU; calculated as a percentage
- Days of mechanical ventilation [ Time Frame: Participants will be followed for the duration of ICU stay, expected average per patient: 10 days ]
- Days of continuous renal replacement therapy [ Time Frame: Participants will be followed for the duration of ICU stay, expected average per patient: 10 days ]
- Neuron Specific Enolase (NSE) blood levels and glycaemic disorders [ Time Frame: NSE collection: Time point A: ICU admission. Time point NSE: 48-72 hours after ICU admission ]To detect a correlation between NSE levels and glycaemic alterations in both diabetic and non diabetic patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02516358
|Contact: Francesca Di Muzio||0467556315; firstname.lastname@example.org|